Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism

Trial Profile

Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Low molecular weight heparin
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PEITHO-2
  • Most Recent Events

    • 01 Dec 2017 According to rationale and trial design published in the Thrombosis and Haemostasis, seventy-seven patients have been enrolled as of Aug 2017.
    • 01 Dec 2017 According to rationale and trial design published in the Thrombosis and Haemostasis, an interim analysis has been planned after enrollment of 20% of targeted population.
    • 01 Dec 2017 Rationale and trial design published in the Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top